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More than two decades ago, Ron Duman’s lab found 
that electroconvulsive shock and some antidepressants 
increased the expression of brain-derived neurotrophic 
factor (BDNF) in the rat brain, and this finding laid the 
foundation for the neurotrophic factor hypothesis of 
antidepressant drug action [1].  Subsequent research by 
several groups has largely confirmed this hypothesis. 
BDNF is the central regulator of neuronal plasticity and 
BDNF signaling through its receptor TRKB is both 
necessary and sufficient for the antidepressant action of 
most, if not all, antidepressants. More recently, Duman’s 
lab searched for other factors that are activated by 
antidepressant treatments and found that vascular 
endothelial growth factor (VEGF) is activated by them and 
needed for their effects [2].   
Through BDNF and VEGF signaling, antidepressants 
promote many forms of neuronal plasticity in many brain 
regions, including synaptogenesis, spine formation, 
branching of axons and dendrites as well as hippocampal 
neurogenesis [3].  By providing an opportunity for activity-
dependent beneficial reorganization of neuronal networks 
underlying mood regulation, this antidepressant-induced 
plasticity may lead to the clinical antidepressant effect [3].  
Plastic changes may take time, and this has been 
thought to produce the delay of days or weeks in the 
appearance in the clinical action of typical 
antidepressants, such as serotonin selective and tricyclic 
antidepressants. In contrast, ketamine has recently been 
shown to produce antidepressant effects that develop 
within minutes and last for several days, even if ketamine 
itself exits the body within hours [4]. Although the temporal 
profile of ketamine is very different from that of 
conventional antidepressants, it was soon shown that 
ketamine, too, activated BDNF signaling and required it for 
its antidepressant effects.  Furthermore, VEGF is also 
required for the rapid effects of ketamine.  In a series of 
experiments to pinpoint the mechanism and site of action 
of ketamine, Duman’s lab has shown that signaling of 
BDNF or VEGF in the rodent median prefrontal cortex 
(mPFC), the region homologous to the mPFC in humans, 
is critical for ketamine- induced antidepressant-like effects 
[4, 5].   
Clinical data supports the role of BDNF and VEGF in 
the pathophysiology of depression. The BDNF Val66Met 
polymorphism has been associated to human depression, 
at least in subgroups [6]. Similarly, a single-nucleotide 
polymorphism in the VEGF gene has been associated to  
an elevated risk to develop depression [7]. Also, an 
interaction between the VEGF-related SNP and a volume 
reduction of the subiculum, an anatomical part of the 
hippocampal formation, in depressive patients has been 
suggested [8]. 
In a manuscript published in this issue, Deyama, 
Duman and coworkers investigate the interrelationship 
between BDNF and VEGF signaling in the prefrontal 
cortex [9].  Using three different tests for antidepressant-
like behavior, they first replicate the findings of the critical 
role of the prefrontal cortex in the antidepressant effects of 
both BDNF and VEGF and then go on to demonstrate that 
a co-injection of an antibody that neutralizes the effects of 
VEGF together with BDNF into the mPFC blocks the 
beneficial effects of BDNF in these tests. They then 
confirmed and extended this finding by showing that a 
selective deletion of VEGF receptor fetal liver kinase-1 
(FLK1) in pyramidal neurons in the mPFC prevents the 
antidepressant-like effects of BDNF administration, 
demonstrating that VEGF signaling is required for the 
antidepressant effects of BDNF.  Unexpectedly, they find 
that co-injection of antibodies against BDNF into the 
mPFC blocks the antidepressant-like effects of VEGF, 
indicating an unusual mutual dependence of these two 
growth factors on each other.  Experiments in cultured 
cortical neurons confirmed this mutual dependence: VEGF 
increased BDNF release in cultured neurons and 
pharmacological blockade of BDNF signaling prevented 
the growth-promoting effects of VEGF in cultured neurons. 
Conversely, BDNF increased VEGF release and drugs 
that block VEGF signaling prevented the neurotrophic 
effects of BDNF.  Together these findings clearly 
demonstrate that the antidepressant and trophic effects of 
BDNF and VEGF depend on each other and are 
intertwined like Siamese twins.  
How is this mutual dependence explained at cellular 
and molecular levels?  Deyama et al. suggest a model 
where glutamate release from a presynaptic neuron in the 
PFC induces the release of both BDNF and VEGF from a 
postsynaptic pyramidal neuron, which leads to the 
activation of their receptors TRKB and FLK1, respectively, 
in the same neurons in an autocrine manner. However, 
both TRKB and FLK1 are receptor tyrosine kinases, and 
the signaling pathways known to be activated by them are 
very similar. Previous work has shown that VEGF, through 
FLK1, activates the phosphoinositide 3-kinase 
(PI3K)/protein kinase B (Akt)/mechanistic target of 
rapamycin complex 1 (mTOR) pathway, which is also 
known to be activated by BDNF-TRKB signaling.  Further, 
FLK1 activates phospholipase C (PLC), leading to the 
release of Ca2+ from intracellular stores, and this pathway, 
too, is activated by TRKB.  If the signaling pathways are 
shared, why is the activation of both receptors required? 
The authors did not perform dose-response studies, so it 
is possible that a higher dose of either growth factor would 
make the other unnecessary.  However, this is unlikely, 
since the dose of BDNF is already relatively high and 
intracortical injection produces a concentration gradient 
with high doses at the site of injection and lower further 
away, which produces a range of concentration in the 
tissue.  There may be pathways less well characterized 
that are preferentially activated by only one of the factors, 
and a synergistic effect of these pathways may be 
necessary for the proper antidepressant effect.   
The results of Deyama et al. do not rule out a 
contribution of additional cell types. The experiments 
presented by the authors establish the localization of the 
FLK1 receptor into pyramidal neurons, but BDNF and 
VEGF are both secreted molecules that can diffuse some 
distant from their release site and therefore activate also 
other cells than the direct pre- and postsynaptic neurons. 
In fact, parvalbumin-containing (PV) interneurons have 
been implicated in the action of ketamine, and although 
these cells do not express BDNF, they abundantly express 
TRKB receptors and VEGF.  Therefore, activity-dependent 
release of BDNF might activate TRKB receptors in PV 
cells, which could stimulate VEGF release and FLK1 
activation in pyramidal neurons (Figure 1).  Alternatively, 
since PV neurons are known to be powerful regulators of 
plasticity of ensembles of pyramidal neurons, VEGF-
induced FLK1 signaling might release BDNF from 
pyramidal neurons that through TrkB activation in PV 
interneurons might set the stage for pyramidal cell 
plasticity and synaptogenesis, which would then be 
necessary for the antidepressant action. The latter 
scenario is consistent with the notion that disinhibition 
through a reduction in PV cell activity is involved in the 
antidepressant effects of ketamine.  Both of these 
arrangements would place BDNF and VEGF signaling into  
a serial as opposed to a parallel pathway, and interruption 
of a serial pathway at any step would be expected to 
disrupt the function of the entire pathway.  Further 
experiments examining the cellular location of the release 
and action of BDNF and VEGF would shed more light into 
these hypothetical scenarios.   
Local injection of BDNF into PFC produces 
antidepressant-like effects and injection of BDNF antibody 
into the PFC blocks the effects of systemic administration 
of ketamine, suggesting that the mPFC is a critical region 
in the brain network mediating antidepressant-like 
behavior.  However, previous studies show that injection 
of BDNF into hippocampus  or midbrain regions also 
produces antidepressant-like effects [3], and these effects 
are unlikely due to diffusion of BDNF into the mPFC after 
injection, because BDNF is very sticky and does not 
diffuse easily. These studies suggest that the network 
mediating antidepressant-like behavior is distributed and 
activation of it by BDNF, and perhaps also by VEGF, at 
several nodes produces similar effects.    
Are the interdependent effects of BDNF and VEGF 
specific for ketamine or are they required for the actions of 
other antidepressants as well?  Deyama et al. suggest that 
the difference between rapid acting and typical 
antidepressants is that both increase the levels of BDNF 
and VEGF, but only ketamine induces their release.  
However, behavioral effects of typical antidepressants 
require BDNF and VEGF signaling [2, 10], and they 
acutely increase BDNF signaling [10], which suggests that 
typical antidepressants do increase BDNF release. 
Therefore, despite of the very different temporal profiles, 
ketamine and typical antidepressants activate very similar 
kind of biological processes. 
The intertwined effects of BDNF and VEGF revealed 
by Deyama et al. [9] suggest that our understanding of 
antidepressant effects is still rudimentary. The processes 
that ultimately differentiate the effects of ketamine from 
typical antidepressants are unclear and why the effects of 
typical antidepressants take so long to develop remains a 
mystery. Neuroplastic processes have been linked to 
depression and the antidepressant action, however, from 
a clinical perspective, the exact meaning of these 
processes in both the development of depression and their 
treatment remains unclear. It is likely that several signaling 
pathways, cell types, networks and brain areas need to be 
brought together for an antidepressant response to 
develop, and even more comprehensive process is likely 
needed for a long-term remission.   
 
 
 
Figure 1: A model for a serial action of BDNF and VEGF in the 
ketamine action. Akt: protein kinase B; BDNF: brain-derived 
neurotrophic factor; Ca2+: calcium ion; FLK1: fetal liver kinase 1; 
mTORC1: mechanistic target of rapamycin complex 1; PI3K: 
phosphoinositide 3-kinase; PLC: phospholipase C; TRKB: 
tropomyosin-related kinase B; VEGF: vascular endothelial 
growth factor.  
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